Challenge
In 2014 Notable raised $22M from tech-focused venture capital firms and built an automated laboratory to more quickly determine which drugs are most likely to work for individual cancer patients. By 2023 the company had undergone multiple leadership changes and a reverse merger leading to a new business plan that was materially different from the original “mail-in test” concept. Key stakeholder, including legacy investors and academic research partners, often had an outdated or imprecise understanding of the company’s strategy and objectives. Notable retained Wyant Simboli to develop a new corporate narrative and revise its external communications in order to clearly articulate its platform and drug development strategy to experienced life-sciences investors.
Solution
Wyant Simboli conducted one-on-one interviews with Notable’s leadership, board members and partners to uncover the company’s story. We developed new key messages and coined the phrase Presponse™ therapeutics to better describe Notable’s innovative responder-focused approach to drug development. We wrote new copy, created compelling visual assets and shot new video and photography at Notable’s offices in California. We worked with Notable’s leadership to team to create a new investor presentation, corporate website and social media campaign to help bring the company’s story to life.
